Development
Predictive Oncology Inc.
POAI
$0.9386
-$0.0114-1.20%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 22.07% | 62.24% | -1.52% | -2.06% | 25.35% |
| Total Depreciation and Amortization | -50.74% | -44.72% | -26.48% | -10.03% | 2.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.71% | -96.82% | -89.74% | 3.28% | -96.23% |
| Change in Net Operating Assets | -123.33% | 87.74% | -8.06% | 552.76% | 220.22% |
| Cash from Operations | -14.66% | -7.20% | -10.80% | 13.60% | 7.82% |
| Capital Expenditure | 96.96% | -35.71% | 46.26% | 70.39% | -23.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | 35.92% | -366.67% | 81.52% |
| Cash from Investing | 97.29% | -37.67% | 41.90% | 99.35% | 22.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | 65.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,605.00% | -- | -- | 37.07% | -127.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.25% | -222.32% | -12.55% | 75.52% | 8.16% |